NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Analysts Remain Bullish On Cardlytics Post Q4 Results

Published 02/03/2022, 17:15
Updated 02/03/2022, 18:10
© Reuters.  Analysts Remain Bullish On Cardlytics Post Q4 Results
CDLX
-

  • Analysts reiterated a Buy on Cardlytics Inc (NASDAQ: CDLX) post Q4 results.
  • Craig-Hallum analyst Jason Kreyer lowered the firm's price target on Cardlytics from $100 to $70 (15% upside) and kept a Buy.
  • The analyst notes quarterly results were strong despite lingering concerns over the supply chain, labor shortages, and omicron issues faced in the quarter.
  • That said, management is leaning into the opportunity with direct investments into sales talent, engineering, and retention. The result is further delays in profitability, Kreyer notes.
  • Despite an outlook for substantially higher revenue this year, he adds that EBITDA losses will exceed last year to afford these investments.
  • Needham analyst Kyle Peterson maintained Cardlytics with a Buy and lowered the price target from $120 to $85 (39% upside).
  • Price Action: CDLX shares traded higher by 13.75% at $61.14 on the last check Wednesday.
Latest Ratings for CDLX DateFirmActionFromTo
Mar 2022NeedhamMaintainsBuy
Aug 2021NeedhamMaintainsBuy
Jun 2021NeedhamInitiates Coverage OnBuy
View More Analyst Ratings for CDLX

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.